Kristian Humer

Kristian Humer joined 4DMT in November 2025 as Chief Financial Officer. He is an accomplished finance executive and biotechnology leader with more than two decades of experience spanning corporate finance, strategic operations, and healthcare investment banking. 

Prior to joining 4DMT, Mr. Humer served as Chief Financial Officer at Foghorn Therapeutics, Inc. from April 2024 to November 2025. Before Foghorn, Mr. Humer was Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc. from July 2021 until September 2023. Prior to Viridian, Mr. Humer spent over two decades in healthcare investment banking. Mr. Humer held progressively senior roles, culminating as Managing Director in Citi’s Healthcare Investment Banking Group, where he worked from 2010 to 2021. He advised clients across the global biopharma sector on strategic initiatives including equity and equity-linked financings, mergers and acquisitions, and other corporate transactions. His prior roles include positions at Lehman Brothers, UBS, and Merrill Lynch. 

Mr. Humer holds an MBA degree from Duke University’s Fuqua School of Business and a BA (Hons) degree in Accounting & Economics from the University of Reading.